Want to see JP:4890 full AI Analyst Report?
4890 Stock Chart & Stats
¥340.00
¥1.00(0.24%)
At close: 4:00 PM EST
¥340.00
¥1.00(0.24%)
Day’s Range― - ―
52-Week Range¥210.00 - ¥478.00
Previous CloseN/A
Volume43.10K
Average Volume (3M)31.02K
Market Cap
¥6.26B
Enterprise Value¥4.83B
Total Cash (Recent Filing)¥969.85M
Total Debt (Recent Filing)¥69.21M
Price to Earnings (P/E)―
Beta0.19
Next Earnings
Aug 12, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-29.59
Shares Outstanding25,969,738
10 Day Avg. Volume26,720
30 Day Avg. Volume31,016
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)8.77
Price to Sales (P/S)37.86
P/FCF Ratio-12.91
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetLow leverage and substantial equity provide a durable financial cushion that reduces refinancing risk and supports continued R&D and commercialization spending. This capital structure increases resilience through operational volatility and gives management time to restore revenues without immediate solvency pressure.
Strong Product-level MarginsA ~66% gross margin implies strong unit economics at the product level, enabling the company to cover fixed costs and eventually convert revenue recovery into sustainable operating profit. Durable gross margins are a structural advantage for long-term profitability if sales scale.
Proven Ability To Reach ProfitabilityA history of profitability and a prior operational rebound indicate the underlying business model can generate earnings when revenue conditions improve. This demonstrates managerial competence and that losses may be cyclical rather than structural, supporting medium-term recovery prospects.
Bears Say
Severe Revenue CollapseAn 85% revenue decline fundamentally erodes scale and undercuts the company’s ability to absorb fixed costs, invest in commercialization, and maintain market share. Such a structural drop raises questions about product demand or market access that could persist absent clear recovery catalysts.
Persistent Negative Operating Cash FlowThree consecutive years of negative operating cash flow indicate ongoing cash burn that threatens financial flexibility. Even with low debt, sustained cash outflows can force dilutive funding, cutbacks to R&D or commercialization, and constrain the company’s ability to execute long-term plans.
Earnings Volatility And Negative ReturnsSharp swings in returns signal unstable profitability driven by volatile revenue or fixed-cost leverage. This unpredictability complicates long-term planning, weakens stakeholder confidence, and can impair hiring, partnerships, and pricing power until consistent positive returns are restored.
Tsubota Laboratory Incorporated News
4890 FAQ
What was Tsubota Laboratory Incorporated’s price range in the past 12 months?
Tsubota Laboratory Incorporated lowest stock price was ¥210.00 and its highest was ¥478.00 in the past 12 months.
What is Tsubota Laboratory Incorporated’s market cap?
Tsubota Laboratory Incorporated’s market cap is ¥6.26B.
When is Tsubota Laboratory Incorporated’s upcoming earnings report date?
Tsubota Laboratory Incorporated’s upcoming earnings report date is Aug 12, 2026 which is in 10 days.
How were Tsubota Laboratory Incorporated’s earnings last quarter?
Tsubota Laboratory Incorporated released its earnings results on May 14, 2026. The company reported -¥9.38 earnings per share for the quarter, missing the consensus estimate of N/A by -¥9.38.
Is Tsubota Laboratory Incorporated overvalued?
According to Wall Street analysts Tsubota Laboratory Incorporated’s price is currently Overvalued.
Does Tsubota Laboratory Incorporated pay dividends?
Tsubota Laboratory Incorporated does not currently pay dividends.
What is Tsubota Laboratory Incorporated’s EPS estimate?
Tsubota Laboratory Incorporated’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tsubota Laboratory Incorporated have?
Tsubota Laboratory Incorporated has 25,969,738 shares outstanding.
What happened to Tsubota Laboratory Incorporated’s price movement after its last earnings report?
Tsubota Laboratory Incorporated reported an EPS of -¥9.38 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.375%.
Which hedge fund is a major shareholder of Tsubota Laboratory Incorporated?
Currently, no hedge funds are holding shares in JP:4890
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tsubota Laboratory Incorporated
Operating from Tokyo, Japan since its establishment in 2012, Tsubota Laboratory Incorporated is dedicated to the research and development of pharmaceutical products and medical devices, specifically targeting the treatment of myopia, dry eyes, and presbyopia.
Technical Analysis
Sundrug Co
―
Sugi Holdings Co
―
TSURUHA Holdings
―
COSMOS Pharmaceutical Corporation
―
KUSURI NO AOKI HOLDINGS CO.,LTD.
―